


Piperine

Cat. No.:	HY-N0144		
CAS No.:	94-62-2		
Molecular Formula:	C ₁₇ H ₁₉ NO ₃		
Molecular Weight:	285.34		
Target:	P-glycoprotein; Autophagy; Endogenous Metabolite		
Pathway:	Membrane Transporter/Ion Channel; Autophagy; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (175.23 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		3.5046 mL	17.5230 mL	35.0459 mL
		5 mM		0.7009 mL	3.5046 mL	7.0092 mL
10 mM			0.3505 mL	1.7523 mL	3.5046 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	Piperine, a natural alkaloid isolated from Piper nigrum L, inhibits P-glycoprotein and CYP3A4 activities with an IC ₅₀ value of 61.94±0.054 µg/mL in HeLa cell.
IC₅₀ & Target	Human Endogenous Metabolite
In Vitro	Piperine has shown to possess in vitro cytotoxic activity and in silico studies. The IC ₅₀ value is found to be 61.94±0.054 µg/mL and in silico studies, it has more number of hydrogen bonds with minimum binding and docking energy and may be

considered as inhibitor of EGFR tyrosine kinase^[1]. Piperine has been found to have immunomodulatory, anti-oxidant, anti-asthmatic, anti-carcinogenic, anti-inflammatory, anti-ulcer, and anti-amoebic properties^[2]. Piperine could enhance the bioavailabilities of other drugs including rosuvastatin, pcurarin and docetaxel (DOX) via inhibition of CYP3A and P-glycoprotein activity^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

At the dose of 3.5 mg/kg, the bioavailability of piperine is calculated to be 25.36%. Its $AUC_{0 \rightarrow t}$ is unproportionally increased with doses, indicating a potential non-linear pharmacokinetics profile of piperine. It is found that the $AUC_{0 \rightarrow t}$ and C_0 of docetaxel and t1/2 of piperine are significantly increased after their combination use, suggesting potential enhanced bioavailability of not only docetaxel but also piperine, which may lead to the overall enhanced pharmacological effects^[3]. The phosphorylation of I- κ B, p65, p38, ERK, and JNK is inhibited by piperine in a dose-dependent manner, indicating that piperine may be a potential anti-inflammatory drug both in endometritis and in other *S. aureus*-induced diseases^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

Standard solution is prepared by dissolving 10 mg of piperine in 100 mL of methanol. The MTT assay is carried out to measure cell viability. Ten thousand cells in 100 μ L of DMEM media are seeded in the wells of a 96-well plate. After 24 h, existing media is removed and 100 μ L of various concentrations of piperine (20–100 μ g/mL) are added and incubated for 48 h at 37 °C in a CO₂ incubator. Control cells are supplemented with 0.05 % DMSO vehicle. At the 48th hour of incubation, MTT (10 μ L of 5 mg/mL) is added to the plate. The contents of the plate are pipetted out carefully, the formazan crystals formed are dissolved in 100 μ L of DMSO, and the absorbance is measured at 550 nm in a microplate reader^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^{[3][4]}

Rats: The stock solutions of piperine (PIP) and docetaxel (DOX) are prepared by dissolving appropriate amount of each authentic compound in DMSO separately at 1 mg/mL. The standard solutions containing both PIP and DOX are prepared by serial dilution of the stock solutions with 0.2% formic acid and acetonitrile (50:50, v/v) to yield concentrations of 25, 50, 100, 200, 400, 800, 1600, 3200, 6400, 12800 ng/mL. 25 Sprague-Dawley rats are divided into five groups receiving DOX (Group DOX 7 iv, 7 mg/kg, i.v.), PIP (Group PIP 35 po, 35 mg/kg, p.o.) and their combined administration (Group DOX+PIP) as well as PIP (Group PIP 3.5 po, 3.5 mg/kg, p.o.) and PIP (Group PIP 3.5 iv, 3.5 mg/kg, i.v.)^[3].

Mice: Piperine is dissolved in 5 mL of tris buffered saline (TBS) at concentrations corresponding to 25, 50, and 100 mg/kg, based on the weight of the mice. After 24 h of *S. aureus* infection in the uterus, the piperine solution is injected intraperitoneally three times every 6 h. A total of 60 female BALB/c mice are used in this study. All mice are maintained on a 12 h light/dark cycle and cafeteria feeding^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- PLoS Biol. 2018 Jul 12;16(7):e2004921.
- Int Immunopharmacol. 2018 Oct 30;65:448-457.
- Biochem Biophys Res Commun. 2019 Aug 20;516(2):365-372.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Paarakh PM, et al. In vitro cytotoxic and in silico activity of piperine isolated from Piper nigrum fruits Linn. In Silico Pharmacol. 2015 Dec;3(1):9. Epub 2015 Oct 29.

[2]. Meghwal M, et al. Piper nigrum and piperine: an update. *Phytother Res.* 2013 Aug;27(8):1121-30.

[3]. Li C, et al. Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. *J Pharm Biomed Anal.* 2016 Sep 5;128:286-93.

[4]. Zhai WJ, et al. Piperine Plays an Anti-Inflammatory Role in Staphylococcus aureus Endometritis by Inhibiting Activation of NF- κ B and MAPK Pathways in Mice. *Evid Based Complement Alternat Med.* 2016;2016:8597208.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA